Blueprint Medicines Corp Stock Price on May 2, 2024
| BPMC Stock | USD 104.96 1.68 1.58% |
Below is the normalized historical share price chart for Blueprint Medicines Corp extending back to April 30, 2015. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Blueprint Medicines stands at 104.96, as last reported on the 18th of May 2024, with the highest price reaching 107.17 and the lowest price hitting 103.23 during the day.
If you're considering investing in Blueprint Stock, it is important to understand the factors that can impact its price. Blueprint Medicines appears to be very steady, given 3 months investment horizon. Blueprint Medicines Corp secures Sharpe Ratio (or Efficiency) of 0.0878, which signifies that the company had a 0.0878% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Blueprint Medicines Corp, which you can use to evaluate the volatility of the firm. Please makes use of Blueprint Medicines' Risk Adjusted Performance of 0.0988, mean deviation of 2.35, and Downside Deviation of 2.85 to double-check if our risk estimates are consistent with your expectations.
The current year's Stock Based Compensation To Revenue is expected to grow to 0.48, whereas Total Stockholder Equity is forecasted to decline to about 124.1 M. . At present, Blueprint Medicines' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 44.91, whereas Price To Sales Ratio is forecasted to decline to 21.28. Blueprint Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 30th of April 2015 | 200 Day MA 73.4716 | 50 Day MA 94.1922 | Beta 0.653 |
Blueprint |
Sharpe Ratio = 0.0878
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BPMC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.04 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.27 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Blueprint Medicines is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Blueprint Medicines by adding it to a well-diversified portfolio.
Price Book 40.9047 | Enterprise Value Ebitda (10.55) | Price Sales 21.4232 | Shares Float 62 M | Wall Street Target Price 119.41 |
Blueprint Medicines Main Headline on 2nd of May 2024
Blueprint Medicines reports strong Q1 results, beating earnings expectations and revenue estimates. |
Blueprint Medicines Valuation on May 2, 2024
It is possible to determine the worth of Blueprint Medicines on a given historical date. On May 2, 2024 Blueprint was worth 103.88 at the beginning of the trading date compared to the closed value of 107.0. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Blueprint Medicines stock. Still, in general, we apply an absolute valuation method to find Blueprint Medicines' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Blueprint Medicines where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Blueprint Medicines' related companies.
| Open | High | Low | Close | Volume | |
| 91.44 | 96.41 | 90.85 | 94.86 | 883,687 | |
05/02/2024 | 103.88 | 110.16 | 100.91 | 107.00 | 2,003,965 |
| 109.82 | 110.93 | 106.07 | 107.19 | 1,004,153 |
| Backtest Blueprint Medicines | | | Blueprint Medicines History | | | Blueprint Medicines Valuation | Previous | Next |
Blueprint Medicines Trading Date Momentum on May 2, 2024
| On May 03 2024 Blueprint Medicines Corp was traded for 107.19 at the closing time. The top price for the day was 110.93 and the lowest listed price was 106.07 . The trading volume for the day was 1 M. The trading history from May 3, 2024 was a factor to the next trading day price growth. The overall trading delta against the next closing price was 0.18% . The overall trading delta against the current closing price is 2.02% . |
Blueprint Medicines Corp Fundamentals Correlations and Trends
By evaluating Blueprint Medicines' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Blueprint Medicines' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Blueprint financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Blueprint Medicines Stock history
Blueprint Medicines investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Blueprint is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Blueprint Medicines Corp will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Blueprint Medicines stock prices may prove useful in developing a viable investing in Blueprint Medicines
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 60.6 M | 43.6 M | |
| Net Loss | -501.8 M | -476.7 M |
Blueprint Medicines Quarterly Net Working Capital |
|
Blueprint Medicines Stock Technical Analysis
Blueprint Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Blueprint Medicines Period Price Range
Low | May 2, 2024
| High |
103.88 | 107.00 |
Blueprint Medicines May 18, 2024 Market Strength
Market strength indicators help investors to evaluate how Blueprint Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Blueprint Medicines shares will generate the highest return on investment. By undertsting and applying Blueprint Medicines stock market strength indicators, traders can identify Blueprint Medicines Corp entry and exit signals to maximize returns
| Accumulation Distribution | 168270.0 | |||
| Daily Balance Of Power | 0.3373 | |||
| Rate Of Daily Change | 1.03 | |||
| Day Median Price | 105.54 | |||
| Day Typical Price | 106.02 | |||
| Price Action Indicator | 3.03 | |||
| Period Momentum Indicator | (2.04) | |||
| Relative Strength Index | 65.85 |
Blueprint Medicines Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Blueprint Medicines' price direction in advance. Along with the technical and fundamental analysis of Blueprint Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Blueprint to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0988 | |||
| Jensen Alpha | 0.3034 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.1511 | |||
| Treynor Ratio | 0.2144 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.82) | Revenue Per Share 4.632 | Quarterly Revenue Growth 0.519 | Return On Assets (0.24) | Return On Equity (0.80) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.